Skip to main content

Funding for Global Research and Training

The Center for Global Health helps reduce the global burden of cancer by strengthening research capacity through funding and training. Below you will find the most recent funding opportunities that are relevant to our work.

Explore a full listing of NIH funding announcements.

Current Funding Opportunities

Learn more about current international cancer research and cancer control funding opportunities developed by CGH, or supported by NCI in collaboration with other NIH Institutes and Centers or research organizations.

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

Funding Announcement: RFA-CA-21-030
This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)

Funding Announcement: RFA-CA-20-031
The purpose of this Funding Opportunity Announcement is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the U.S.-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs.

For additional information, please download the following resources: D43 Pre-Application Webinar Slides and Frequently Asked Questions.

Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control

Notice Number: NOT-CA-21-033
The NOSI: Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control announces an opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-033.html

For additional information, view Frequently Asked Questions for Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control.

International Research Scientist Development Award (IRSDA) (K01) 

Funding Announcements: PAR-21-104 (Independent Clinical Trial Not Allowed) PAR-21-105 (Independent Clinical Trial Required) 
The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty for an intensive, mentored research career development experience in a low- or middle-income country (LMIC) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors. 

The East Asia Science and Innovation Area Joint Research Program

Apply at: https://www.the-easia.org/jrp/
The East Asia Science and Innovation Area Joint Research Program, or e-ASIA JRP call for applications is now open. The e-Asia JRP is a multilateral international joint initiative between a number of public funding organizations of the East Asia Summit (EAS) member countries. e-ASIA JRP works to formulate and support international joint research in the East Asian region as well as research exchanges through workshops and other activities. Research projects are selected through open calls for proposals and subsequently supported by co-funding from the participating agencies. The NCI is participating in the e-ASIA JRP through in-kind and re-budgeting only and does not anticipate new awards to support e-ASIA projects, though new funding for international collaborative partners is available from several participating funding agencies. The application form and more information about the JRP can be found here: https://www.the-easia.org/jrp/. For additional information about the solicitation guidelines, please visit https://www.the-easia.org/jrp/pdf/cfp10/guideline_10th_health.pdf.

Notice of Special Interest (NOSI): Innovative Molecular Analysis Technologies for Low-Resource Settings Globally

Notice Number: NOT-CA-21-025
With this NOSI, the NCI Center for Global Health (CGH) is seeking to leverage ongoing Innovative Molecular Analysis Technologies (IMAT) program activities to stimulate exploratory research on technology platforms relevant for global oncology and appropriate for use in low-resource settings globally. CGH is prepared to support highly meritorious IMAT R21 applications with the goal of helping drive innovation in this field and to enrich the pool of investigators participating in the NCI-sponsored Affordable Cancer Technologies (ACTs) Program. Notice: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-025.html

Notice of Special Interest: Administrative Supplement Opportunity to Support Global Cancer Stigma Research

Notice Number: NOT-CA-21-026
This Notice of Special Interest: Administrative Supplement Opportunity to Support Global Cancer Stigma Research informs current awardees that NCI is providing an opportunity for supplemental funding to support exploratory research studies to expand the current understanding of cancer stigma, assess its impact on cancer control and prevention, and develop stigma-reduction interventions to improve cancer outcomes in low- and middle-income countries. The goals of these administrative supplements are to: 1) elucidate the etiology and perpetuation of cancer stigma; 2) measure the impact of cancer stigma on physical and mental well-being and associated health behaviors of patients; 3) identify mechanisms and pathways by which stigma is a barrier to cancer prevention, treatment, palliation, and survivorship; and 4) develop interventions to reduce cancer stigma and improve cancer outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-026.html

Notice of Special Interest: Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program

Notice Number: NOT-OD-21-021
The AKA-NIH Partnership Program seeks to encourage increased collaborative research between investigators in the U.S. and Finland. This is to be facilitated through the submission of grant applications from U.S. institutions that include collaboration with Finnish investigators selected by AKA to participate in the joint research program. NIH will support the project through regular investigator-initiated NIH application processes and review. AKA will fully fund Finnish investigators on collaborative grant applications that are selected for funding by participating NIH Institutes and Centers (ICs), while NIH will fund the U.S. component. Examples of research support can be found at https://grants.nih.gov/grants/guide/notice-files/not-od-21-021.html.

Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-CA-20-042
The National Cancer Institute is issuing this NOSI to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer. For more information visit: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-042.html.

Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-CA-20-043
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this NOSI to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). To accelerate the development of promising technologies, the NCI encourages applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19). For more information visit: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-043.html.

Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD)

Notice Number: NOT-CA-20-031
The purpose of this Notice is to inform potential applicants of the special interest of the National Cancer Institute in encouraging the submission of applications that advance early detection of head and neck cancer (HNC) by applying genomics, epigenomics, transcriptomics, proteomics, and molecular signatures to clinical studies for differentiating benign lesions from malignant ones. The initiative also encourages novel basic research for HNC cancer prevention as well as the development of molecular markers to combine with current available HNC detection methods for increasing sensitivity and specificity.

Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments

NOT-CA-20-025
This Notice seeks to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs) and in low-resource settings. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings. The research projects on which these applications will be based should be focused on dissemination and implementation research for the primary and secondary prevention of cancer in LMICs and/or in populations facing conditions of vulnerability in high-income countries.

Interested applicants must submit applications for this initiative using one of the following Dissemination and Implementation Research in Health funding opportunity announcements: PAR-19-274 (R01 Clinical Trial Optional); PAR-19-275 (R21 Clinical Trial Optional); PAR-19-276 (R03 Clinical Trial Not Allowed). For more information visit: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-025.html.

Microbial-based Cancer Therapy - Bugs as Drugs (R01/R21)

The purpose of this funding opportunity announcement is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. PAR-19-194 (R21 for early stage research); PAR-19-193 (R01 for mature projects). Examples of Applications: (RO1, R21s).

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (Clinical Trial Optional)

These funding opportunities encourage Small Business Innovation Research (SBIR and STTR) grant applications from small business concerns (SBCs) proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the U.S. PAR-18-801 (R43/R44); PAR-18-802 (R41/42). For more information about these funding opportunities, download presentations from the NCI SBIR-CGH Joint Informational Webinar: SBIR-CGH Webinar1; SBIR-CGH Webinar2.

Note: Direct-to-Phase II is allowed for PAR-18-801 https://grants.nih.gov/grants/guide/notice-files/NOT-CA-19-003.html.

Dissemination and Implementation Research in Health (Clinical Trial Optional)

This funding opportunity encourages research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings. PAR-19-274 (R01); PAR-19-275 (R21).

Dissemination and Implementation Research in Health (R03)

This funding opportunity encourages research grant applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement evidence-based health practices for public health, clinical practice, and community settings.    

International Research Scientist Development Award (K01)

This funding opportunity supports intensive, mentored research career development for early stage investigators committed to a cancer research career. PAR-18-539 (Independent clinical trial not allowed). PAR-18-540 (Independent clinical trial required). For additional information, please visit Frequently Asked Questions for the International Research Scientist Development Award.

Clinical and Epidemiological Research on Chronic Disease in the Caribbean (R01)

This funding opportunity supports U.S.- Caribbean collaborative research to develop or extend cohort or surveillance studies on chronic disease in the Caribbean region, aligned with existing, publicly available U.S. datasets.

Cancer Moonshot℠ Funding Opportunities

These funding opportunities highlight research initiatives that align with the efforts of the Cancer Moonshot. Supported with existing or 21st Century Cures Act funds, featured announcements include open funding opportunities.

NIH Support for Conferences and Scientific Meetings (R13)

This funding opportunity supports high quality scientific conferences that are relevant to the NIH's mission and to the public health.

Previously Funded Initiatives

Learn more about CGH’s previously funded research grants and initiatives. Download list of CGH previously funded initiatives.

Training Opportunities

Learn more about training opportunities available to U.S. and international students, scientists, and health care professionals. 

Short-Term Scientist Exchange Program

The Short-Term Scientist Exchange Program at the Center for Global Health, National Cancer Institute, promotes collaborative research between researchers at the NCI and foreign cancer researchers.

NCI Summer Curriculum in Cancer Prevention Program

This program offers two short-term cancer prevention training courses in Rockville, MD to international scientists and healthcare professionals from LMICs and the All-Ireland Cancer Consortium (AICC).

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Funding for Global Research and Training was originally published by the National Cancer Institute.”